As a dual tyrosine kinase inhibitor, this agent’s intended mechanism of action is to interrupt the HER2/neu and EGFR pathways, and was approved to be prescribed for breast cancer and other solid tumors by the FDA in 2007. The gene discussed is ERBB2; the disease is breast carcinoma.